-+ 0.00%
-+ 0.00%
-+ 0.00%

Saito Biotech announced that its holding subsidiary Shandong Sirui Pharmaceutical Co., Ltd. recently received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for fluticasone furoate issued by the State Drug Administration. Fluticasone furoate is used in nasal sprays and inhaled powders to treat allergic rhinitis, asthma, etc. The approval will enrich the company's product line and enhance market competitiveness. Currently, there is no sale of this API, and there is uncertainty about the production and sales time due to factors such as GMP inspection progress and market environment. Global demand in 2024 will be around 500 kg.

Zhitongcaijing·07/22/2026 08:09:09
Listen to the news
Saito Biotech announced that its holding subsidiary Shandong Sirui Pharmaceutical Co., Ltd. recently received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for fluticasone furoate issued by the State Drug Administration. Fluticasone furoate is used in nasal sprays and inhaled powders to treat allergic rhinitis, asthma, etc. The approval will enrich the company's product line and enhance market competitiveness. Currently, there is no sale of this API, and there is uncertainty about the production and sales time due to factors such as GMP inspection progress and market environment. Global demand in 2024 will be around 500 kg.